iCAD, Inc. (NASDAQ:ICAD) Short Interest Down 14.5% in January

iCAD, Inc. (NASDAQ:ICAD) saw a large decrease in short interest during the month of January. As of January 15th, there was short interest totalling 215,000 shares, a decrease of 14.5% from the December 31st total of 251,500 shares. Based on an average daily trading volume, of 268,000 shares, the short-interest ratio is presently 0.8 days. Currently, 0.9% of the company’s stock are sold short.

Hedge Funds Weigh In On iCAD

Hedge funds have recently bought and sold shares of the business. waypoint wealth counsel boosted its stake in shares of iCAD by 44.0% in the 4th quarter. waypoint wealth counsel now owns 14,400 shares of the technology company’s stock worth $26,000 after buying an additional 4,400 shares during the last quarter. Essex LLC purchased a new position in shares of iCAD in the 3rd quarter worth $216,000. Finally, Summit Trail Advisors LLC purchased a new position in shares of iCAD in the 4th quarter worth $214,000. Hedge funds and other institutional investors own 24.61% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com cut iCAD from a “hold” rating to a “sell” rating in a research note on Friday.

iCAD Price Performance

iCAD stock traded up $0.03 during mid-day trading on Friday, reaching $3.17. The stock had a trading volume of 918,369 shares, compared to its average volume of 664,845. The company has a market capitalization of $84.13 million, a price-to-earnings ratio of -24.35 and a beta of 1.40. iCAD has a one year low of $1.18 and a one year high of $3.78. The company has a 50-day moving average price of $1.96 and a two-hundred day moving average price of $1.72.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.